Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation

Thrombosis Research

Volumn 129, Issue 1, 2012, Pages 9-16

  Garcia, David A ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Atrial fibrillation; Oral anticoagulant; Risk stratification; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; DRUG ABSORPTION; EMBOLISM; EMBOLISM PREVENTION; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELF CARE; SELF MONITORING; STROKE; UNITED STATES; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; GUIDELINE ADHERENCE; HEMORRHAGE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84655160825     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.09.023     Document Type: Review

References (70)

1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
2. A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, and J.V. Selby Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375 (Pubitemid 32424106)
3. V. Fuster, L.E. Ryden, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen ACC/ AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 2006 e257 e354
4. G.V. Naccarelli, D.L. Wolbrette, S. Samii, J.E. Banchs, E. Penny-Peterson, and M.D. Gonzalez New antiarrhythmic treatment of atrial fibrillation Expert Rev Cardiovasc Ther 5 2007 707 714 (Pubitemid 47050181)
5. D.E. Singer, G.W. Albers, J.E. Dalen, M.C. Fang, A.S. Go, and J.L. Halperin Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 546S 592S (Pubitemid 351892972)
6. D.A. Dulli, H. Stanko, and R.L. Levine Atrial fibrillation is associated with severe acute ischemic stroke Neuroepidemiology 22 2003 118 123 (Pubitemid 36302428)
7. H.J. Lin, P.A. Wolf, M. Kelly-Hayes, A.S. Beiser, C.S. Kase, and E.J. Benjamin Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 1996 1760 1764 (Pubitemid 26332500)
8. A.M. Holbrook, J.A. Pereira, R. Labiris, H. McDonald, J.D. Douketis, and M. Crowther Systematic overview of warfarin and its drug and food interactions Arch Intern Med 165 2005 1095 1106 (Pubitemid 40720733)
9. M.C. Fang, R.S. Stafford, J.N. Ruskin, and D.E. Singer National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation Arch Intern Med 164 2004 55 60 (Pubitemid 38081240)
10. A.S. Go, E.M. Hylek, L.H. Borowsky, K.A. Phillips, J.V. Selby, and D.E. Singer Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934 (Pubitemid 30005032)
11. D. Deplanque, D. Leys, L. Parnetti, R. Schmidt, J. Ferro, and J. De Reuck Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study Br J Clin Pharmacol 57 2004 798 806 (Pubitemid 38748048)
12. M.C. Fang, A.S. Go, Y. Chang, E.M. Hylek, L.E. Henault, and N.G. Jensvold Death and disability from warfarin-associated intracranial and extracranial hemorrhages Am J Med 120 2007 700 705 (Pubitemid 47176507)
13. L. Wallentin, S. Yusuf, M.D. Ezekowitz, M. Alings, M. Flather, and M.G. Franzosi Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
14. H.D. White, M. Gruber, J. Feyzi, S. Kaatz, H.F. Tse, and S. Husted Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V Arch Intern Med 167 2007 239 245
15. D. Garcia Novel anticoagulants and the future of anticoagulation Thromb Res 123 Suppl 4 2009 S50 S55
16. R. Fuller, N. Dudley, and J. Blacktop Avoidance hierarchies and preferences for anticoagulation-semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarin Age Ageing 33 2004 608 611 (Pubitemid 39504295)
17. D.E. Singer, Y. Chang, M.C. Fang, L.H. Borowsky, N.K. Pomernacki, and N. Udaltsova The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann Intern Med 151 2009 297 305
18. B.F. Gage, C. van Walraven, L. Pearce, R.G. Hart, P.J. Koudstaal, and B.S. Boode Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin Circulation 110 2004 2287 2292 (Pubitemid 39407328)
19. L.B. Goldstein, C.D. Bushnell, R.J. Adams, L.J. Appel, L.T. Braun, and S. Chaturvedi Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke 42 2011 517 584
20. R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 1999 492 501 (Pubitemid 29482392)
21. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, and S. Ernst Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
22. J. Mant, F.D. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice, and G.Y. Lip Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial Lancet 370 2007 493 503 (Pubitemid 47212371)
23. S. Connolly, J. Pogue, R. Hart, M. Pfeffer, S. Hohnloser, and S. Chrolavicius Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
24. L.S. Wann, A.B. Curtis, K.A. Ellenbogen, N.A. Estes III, M.D. Ezekowitz, and W.M. Jackman ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 2011 e269 e367
25. M.C. Fang, A.S. Go, Y. Chang, L. Borowsky, N.K. Pomernacki, and D.E. Singer Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation J Am Coll Cardiol 51 2008 810 815 (Pubitemid 351253746)
26. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870 (Pubitemid 32537350)
27. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators JAMA 279 1998 1273 1277
28. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
29. J.B. Olesen, G.Y. Lip, M.L. Hansen, P.R. Hansen, J.S. Tolstrup, and J. Lindhardsen Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study BMJ 342 2011 d124
30. J. Monette, J.H. Gurwitz, P.A. Rochon, and J. Avorn Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners J Am Geriatr Soc 45 1997 1060 1065 (Pubitemid 27377551)
31. D.C. McCrory, D.B. Matchar, G. Samsa, L.L. Sanders, and E.L. Pritchett Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly Arch Intern Med 155 1995 277 281
32. M. Kutner, G. Nixon, and F. Silverstone Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation Arch Intern Med 151 1991 1950 1953
33. R.J. Beyth, and C.S. Landefeld Outcomes of warfarin therapy: lessons from the real world Mayo Clin Proc 70 1995 806 808
34. P.J. Devereaux, D.R. Anderson, M.J. Gardner, W. Putnam, G.J. Flowerdew, and B.F. Brownell Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study BMJ 323 2001 1218 1222
35. S. Vasishta, F. Toor, A. Johansen, and M. Hasan Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people Arch Gerontol Geriatr 33 2001 219 226 (Pubitemid 32842905)
36. J. Somerfield, P.A. Barber, N.E. Anderson, A. Kumar, D. Spriggs, and A. Charleston Not all patients with atrial fibrillation-associated ischemic stroke can be started on anticoagulant therapy Stroke 37 2006 1217 1220 (Pubitemid 43731865)
37. M. Man-Son-Hing, G. Nichol, A. Lau, and A. Laupacis Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls Arch Intern Med 159 1999 677 685 (Pubitemid 29177656)
38. R.J. Beyth, L.M. Quinn, and C.S. Landefeld Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am J Med 105 1998 91 99 (Pubitemid 28405230)
39. B.F. Gage, Y. Yan, P.E. Milligan, A.D. Waterman, R. Culverhouse, and M.W. Rich Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J 151 2006 713 719 (Pubitemid 43290267)
40. T.I. Shireman, J.D. Mahnken, P.A. Howard, T.F. Kresowik, Q. Hou, and E.F. Ellerbeck Development of a contemporary bleeding risk model for elderly warfarin recipients Chest 130 2006 1390 1396 (Pubitemid 44786731)
41. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
42. W.L. Baker, D.A. Cios, S.D. Sander, and C.I. Coleman Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 2009 244 252
43. D.B. Matchar Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial Card Electrophysiol Rev 7 2003 379 381
44. M.B. Nichol, T.K. Knight, T. Dow, G. Wygant, G. Borok, and O. Hauch Quality of anti-coagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care Ann Pharmacother 42 2008 62 70
45. G.P. Samsa, D.B. Matchar, L.B. Goldstein, A.J. Bonito, L.J. Lux, and D.M. Witter Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities Arch Intern Med 160 2000 967 973 (Pubitemid 30191925)
46. C. Heneghan, P. Alonso-Coello, J.M. Garcia-Alamino, R. Perera, E. Meats, and P. Glasziou Self-monitoring of oral anticoagulation: a systematic review and meta-analysis Lancet 367 2006 404 411 (Pubitemid 43184260)
47. D.B. Matchar, A. Jacobson, R. Dolor, R. Edson, L. Uyeda, and C.S. Phibbs Effect of home testing of international normalized ratio on clinical events N Engl J Med 363 2010 1608 1620
48. D.B. Matchar, A.K. Jacobson, R.G. Edson, P.W. Lavori, J.E. Ansell, and M.D. Ezekowitz The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481-the Home INR Study (THINRS) J Thromb Thrombolysis 19 2005 163 172 (Pubitemid 41149478)
49. K.N. Kangelaris, S. Bent, R.L. Nussbaum, D.A. Garcia, and J.A. Tice Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin J Gen Intern Med 24 2009 656 664
50. J.L. Anderson, B.D. Horne, S.M. Stevens, A.S. Grove, S. Barton, and Z.P. Nicholas Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 2007 2563 2570 (Pubitemid 350179221)
51. Pradaxa (dabigatran etexilate). Prescribing information http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf Accessed on October 25, 2010
52. Boehringer Ingelheim. (2011). Pradaxa® (dabigatran etexilate) revolutionizes stroke prevention in atrial fibrillation Retrieved from http://www.boehringer-ingelheim.com/news/news-releases/press-releases/2011/ 26-august-2011-dabigatran.html
53. J. Stangier, K. Rathgen, H. Stahle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303 (Pubitemid 47283865)
54. M. Sobieraj-Teague, M. O'Donnell, and J. Eikelboom New anticoagulants for atrial fibrillation Semin Thromb Hemost 35 2009 515 524
55. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
56. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, and L. Wallentin Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
57. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786 (Pubitemid 351930852)
58. A.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
59. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775 (Pubitemid 351930851)
60. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
61. Xarelto (rivaroxaban). Prescribing information http://www.xareltohcp.com/ sites/default/files/pdf/xarelto-0.pdf#zoom=100 Accessed July 18, 2011
62. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation N Engl J Med 365 2011 883 891
63. New Drug Application Submitted to FDA for Rivaroxaban for Prevention of Stroke in Patients with Atrial Fibrillation. Johnson &Johnson, January 5, 2011 Available at: http://www.jnj.com/connect/news/product/new-drug-application- submitted-to-fda-for-rivaroxaban-for-prevention-of-stroke-in-patients-with- atrial-fibrillation Accessed on January 27, 2011
64. S.J. Connolly, J. Eikelboom, C. Joyner, H.C. Diener, R. Hart, and S. Golitsyn Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
65. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
66. G. Merli, A.C. Spyropoulos, and J.A. Caprini Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations Ann Surg 250 2009 219 228
67. J.I. Weitz, S.J. Connolly, I. Patel, D. Salazar, S. Rohatagi, and J. Mendell Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Thromb Haemost 104 2010 633 641
68. J.V. Freeman, R.P. Zhu, D.K. Owens, A.M. Garber, D.W. Hutton, and A.S. Go Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11
69. S.V. Sorensen, A.R. Kansal, S. Connolly, S. Peng, J. Linnehan, and C. Bradley-Kennedy Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective Thromb Haemost 105 2011 908 919
70. I. Savelieva, and J. Camm Update on atrial fibrillation: part I Clin Cardiol 31 2008 55 62 (Pubitemid 351320498)